Ionis Pharma Reports Approval Of WAINZUA In The EU - Quick Facts

(RTTNews) - Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca's WAINZUA has been approved in the European Union for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN.

WAINZUA was approved under the brand name WAINUA for the treatment of ATTRv-PN in the U.S. in December 2023 and has gained approvals in additional countries worldwide.

For More Such Health News, visit rttnews.com.